医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Arcadia Biosciences and Mahyco Achieve Key Milestone for Salt Tolerant Rice

2014年01月22日 PM09:25
このエントリーをはてなブックマークに追加


 

DAVIS, Calif. & JALNA, India

Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, and Maharashtra Hybrid Seeds Co. Ltd. (Mahyco) today announced the achievement of a key milestone in the development of Salt Tolerant rice.

Arcadia’s Salt Tolerance (ST) technology enables plants to produce increased yields under saline water and soil conditions, expanding the range of usable acreage for crop production and reducing requirements for fresh water.

In achieving this key milestone, Mahyco demonstrated that Arcadia’s ST technology significantly increased plant growth and yield in multiple rice lines developed by Mahyco. Rice varieties incorporating ST technology showed substantial increases in key plant performance measures.

Rice is the world’s second-largest crop, grown on 161 million hectares annually. It plays a critical role in food security for more than half of the world’s population. India, with a population of more than 1.2 billion, is the second most populous country in the world. The United Nations Food and Agriculture Organization (FAO) estimates that 221 million people in India, or about one-fifth of the population, are undernourished. As such, there is significant pressure on Indian farmers to increase agricultural productivity.

“With the growing demands on fresh water and land resources for agriculture, the ability to maintain high crop yields in salt-impacted environments is critical,” said Eric Rey, president and CEO of Arcadia Biosciences. “This key technology is just one of a number of improvements Arcadia and Mahyco are developing together to increase farm productivity and reduce the overall environmental impact of agriculture in the region,” he added.

“With this milestone, we are closer to bringing the benefits of this technology to the farmers who are challenged with increased salinity in their farms and improving the overall productivity of the crop,” said Usha Zehr, chief technology officer of Mahyco.

About Arcadia Biosciences, Inc.

Based in Davis, Calif., Arcadia Biosciences is an agricultural technology company focused on the development of agricultural products that improve the environment and enhance human health. Arcadia’s agronomic traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salt Tolerance, Heat Tolerance, and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia’s health technologies and products create healthier nutritional ingredients and foods with lower production costs. For more information visit www.arcadiabio.com.

About Mahyco

Established in 1964 by Dr. Badrinarayan R. Barwale, Mahyco is a pioneer and leader in the Indian seed industry. The company strives to provide quality seeds. Since its inception it has been engaged in plant genetic research and production of quality seeds for the farming community of India. Currently, it is engaged in the research, production, processing and marketing of approximately 115 products in 30 crop species including cereals, oilseeds, fiber and vegetables. Mahyco is also developing genetically enhanced crops with the use of gene transfer technology. Mahyco has a national presence with its network across the country. For more information visit www.mahyco.com.

CONTACT

Arcadia Biosciences, Inc.
Jeff Bergau
+1-312-217-0419
jeff.bergau@arcadiabio.com
or
Mahyco
Usha
Barwale Zehr
+91-24-8226-2371 / +91-22-6757-3000
usha.zehr@mahyco.com
/ info@mahyco.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗